Table 4.
Demographics and baseline characteristics of patients included in the studies used in the final qualitative synthesis
| Study | Previous treatment failures | Anti-CGRP mAb | Mean age | N | Femalea | Mean MMD at baseline | Mean MAMD at baseline | Years since initial migraine diagnosis | MSQ |
|---|---|---|---|---|---|---|---|---|---|
| Ashina et al. NCT 02,066,415 [67] | ≥ 2 | Placebob | 42.9 (11.5) | 286 | 78.2% | 18.3 (4.5) | 11.4 (7.4) | 24.0 (12.9) | No data |
|
Erenumab 70 mgb |
42.9 (11.2) | 191 | 90.3% | 18.0 (4.4) | 10.5 (7.2) | 25.2 (13.2) | |||
|
Erenumab 140 mgb |
44.2 (10.6) | 190 | 89.1% | 18.8 (4.4) | 12.4 (7.2) | 24.6 (11.7) | |||
| Ferrari et al. FOCUS (NCT03308968) [68] | 2–4 | Placebob | 46.8 (11.1) | 279 | 83% | 14.3 (6.1) | 12.3 (6.3) | 24.3 (13.6) | No data |
| Fremanezumab (quarterly treatment)c | 45.8 (11.0) | 276 | 84.1% | 14.1 (5.6) | 12.8 (6.2) | 24.3 (12.8) | |||
| Fremanezumab (monthly treatment)d | 45.9 (11.1) | 283 | 83.5% | 14.1 (5.6) | 12.2 (6.0) | 24.0 (13.7) | |||
| Ruff et al. REGAIN (NCT02614261) [69] | ≥ 2 | Placebob | 43.9 (11.8) | 558 | 88.7% | 19.6 (4.71) | 15.8 (6.0) | 24.3 (13.1) | 37.5 (17.7) |
| Galcanezumab 120 mgb | 42.8 (11.3) | 278 | 91.9% | 20.0 (4.3) | 16.6 (5.6) | 22.6 (13.3) | 39.5 (17.2) | ||
| Galcanezumab 240 mgb | 42.1 (12.6) | 277 | 82.9% | 19.0 (4.9) | 14.7 (5.8) | 21.3 (13.4) | 38.3 (16.9) | ||
|
Mulleners et al. CONQUER (NCT03559257) [70] |
2–4 | Placebob | 44.8 (13.1) | 98 | 87% | 18.1 (4.7) | 16.4 (6.0) | 24.9 (14.9) | 40.5 (19.7) |
| Galcanezumab 120 mgb | 45.8 (11.6) | 95 | 87% | 19.2 (4.7) | 16.0 (6.9) | 24.2 (13.9) | 41.9 (17.0) |
Data are presented as mean (SD) unless stated otherwise
Anti-CGRP mAb calcitonin gene-related peptide monoclonal antibodies, MMD monthly migraine days, MAMD, monthly acute migraine-specific medication days, MSQ Migraine-specific Quality of Life Questionnaire, SD, standard deviation, N number of patients
aPercentages represent categorical variables compared to the total number of patients in each treatment subgroup
bMonthly administration for 3 months
cFirst dose consists of fremanezumab 675 mg and placebo in the remaining 2 months
dFirst dose consists of fremanezumab 675 mg followed by monthly fremanezumab 225 mg for 2 months